Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 2, 1996, Pages 728-738

  Bores, Gina M ^a   Huger, Francis P ^a   Petko, Wayne ^a   Mutlib, Abdul E ^a   Camacho, Fernando ^a   Rush, Douglas K ^a   Selk, David E ^a   Wolf, Veronica ^a   Kosley Jr , Raymond W ^a   Davis, Larry ^a   Vargas, Hugo M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; HYPOTHERMIA; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; STEM CELL;

ALZHEIMER DISEASE; ANIMALS; AVOIDANCE LEARNING; BODY TEMPERATURE; CHOLINESTERASE INHIBITORS; GALANTAMINE; HUMANS; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SCOPOLAMINE;

EID: 12644273785     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. BARTUS, R. T., DEAN, R. L., BEER, B. AND LIPPA, A. S.: The cholinergic hypothesis of geriatric memory dysfunction Science (Wash. DC) 217: 408-417, 1982.
2. BEATTY, W W., BUTTERS, N. AND JANOWSKY, D. S.: Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behav. Neural Biol. 45: 196-211, 1986.
3. BECKER, R. E. AND GIACOBINI, E.: Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: Clinical, pharmacological, and therapeutic aspects. Drug Dev. Res. 12: 163-195, 1988.
4. BICKEL, U., THOMSEN, T., FISCHER, J. P., WEBER, W. AND KEWITZ, H.: Galanthamine: Pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 30: 447-454, 1991b.
5. BICKEL, U., THOMSEN, T., WEBER, W., FISCHER, J. P., BACHUS, R., NITZ, M. AND KEWITZ, H.: Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin. Pharmacol. Ther. 50: 420-428, 1991a.
6. BORES, G., HUGER, F., PETKO, W., MUTLIB, A., CAMACHO, F., SELK, D., TABERNA, V., KOSLEY, R., DAVIS, L. AND VARGAS, H.: Evaluation of P11012 and P11149 for the treatment of Alzheimer's disease. Abstract p. 114, Third International Springfield Symposium on Advances in Alzheimer Therapy, Springfield, Illinois, May 11-15, 1994.
7. BOWEN, D. M., SPILLANE, J. A., CURZON, G., MEIER-RUGE, W., WHITE, P., IWANGOFF, P. AND DAVISON, A. N.: Accelerated aging or selective neuronal loss as an important cause of dementia. Lancet i: 11, 1979.
8. BRADFORD, M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
9. CAMACHO, F., SMITH, C. P., VARGAS, H. M. AND WINSLOW, J. T.: Combined cholinesterase inhibitors and alpha-2-adrenoceptor antagonists enhance passive avoidance in the rat. Psychopharmacology, 124: 1996.
10. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
11. CHOPIN, P. AND BRILEY, M.: Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology 106: 26-30, 1992.
12. COYLE, J. T., PRICE, D. L. AND DELONG, M. R.: Alzheimer's disease: A disorder of cortical cholinergic innervation. Science (Wash. DC) 219: 1184-1190, 1983.
13. CUMIN, R., BANDLE, E. F., GAMZU, E. AND HAEFELY, W. E.: Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology 78: 104-111, 1982
14. DAVIES, P. AND MALONEY, A. J. F.: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet ii: 1403, 1976.
15. DAVIS, L., FINK, D., RAUCKMAN, B., TABERNA, V., TEGELER, J., BORES, G., CAMACHO, F., PETKO, W., SELK, D., VARGAS, H. AND KOSLEY, R.: Galanthamine derivatives as agents for the treatment of Alzheimer's disease. Abstracts of the 209th American Chemical Society, Anaheim, CA, April 2-6, MEDI 91, 1995.
16. DRESSEL, T. D., GOODALE, R. L., BORNER, J W. AND ETANI, S. E.: A study of the cholinesterases of the canine pancreatic sphincters and the relationship between reduced butyrylcholinesterase activity and pancreatic ductal hypertension. Ann. Surg. 192: 614-618, 1980.
17. ELLMAN, G. L., COURTNEY, K. D., ANDRES, V., JR. AND FEATHERSTONE, R. M.: A new and rapid colormetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7: 88-95, 1961.
18. FIELDING, S., LAL, H., DOBRIN, E. I. AND NIEMEGEERS, C. J. E.: Preclinical neuropsychopharmacology of neuroleptics: Screening tests using higher animals. In Neuroleptics, Industrial Pharmacology, ed. by S. Fielding and H. Lal, vol. 1, pp. 64-90, Future Publishing Co , Mount Kisco, NY, 1974.
19. FLICKER, C., SERBY, M. AND FERRIS, S H.: Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology 100: 243-250, 1990.
20. FLOOD, J. F. AND CHERKIN, A.: Scopolamine effects on memory retention in mice: A model of dementia? Behav. Neural Biol. 45: 169-184, 1986.
21. GORDON, C. J.: Thermoregulation in laboratory mammals and humans exposed to anticholinesterase agents. Neurotoxicol. Teratol. 16: 427-453, 1994.
22. GUPTA, R. C. AND DETTBARN, W. D.: Iso-OMPA-induced potentiation of soman toxicity in rat. Arch. Toxicol. 61: 58-62, 1987.
23. HAN, S. Y., SWEENEY, J. E., BACHMAN, E. S., SCHWEIGER, E. J., FORLONI, G., COYLE, J. T., DAVIS, B. M. AND JOULLIE, M. M.: Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives. A potential application in Alzheimer's disease. Eur. J. Med. Chem. 27: 673-687, 1992.
24. IRWIN, S.: Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13: 222-257, 1968.
25. JAFFE, J. H. AND MARTIN, W. R.: Opioid analgesics and antagonists. In The Pharmacological Basis of Therapeutics, ed. by A. G. Gilman, L. S. Goodman and A. Gilman, pp. 494-534, Macmillan Publishing Co., Inc., New York, NY, 1980.
26. KATZMAN, R.: The prevalence and malignancy of Alzheimer's disease. Arch. Neurol. 33: 217-218, 1976.
27. KEWITZ, H., WILCOCK, G. AND DAVIS, B.: Galanthamine in Alzheimer's disease. In Alzheimer Disease: Therapeutic Strategies, ed. by E. Giacobini and R. Becker, pp. 140-144, Birkäuser, Boston, MA, 1994.
28. KOELLE, W. A., KOELLE, G. B. AND SMYRL, E. G.: Effects of persistent selective suppression of ganglionic butyrylcholinesterase on steady state and regenerating levels of acetylcholinesterase: Implications regarding function of butyrylcholinesterase and regulation of protein synthesis. Proc. Natl. Acad. Sci. U.S.A. 73: 2936-2938, 1976.
29. ®) following single intravenous and oral administration in rats. Pharmacology (Basel) 32: 301-306, 1986.
30. MIHAILOVA, D., YAMBOLIEV, I., ZHIVKOVA, Z., TENCHEVA, J. AND JOVOVICH, V.: Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology (Basel) 39: 50-58, 1989.
31. PLUM, F.: Dementia, an approaching epidemic. Nature (Lond.) 279: 372-373, 1979.
32. POMPONI, M., GIACOBINI, E. AND BBUFANI, M.: Present state and future development of the therapy of Alzheimer disease. Aging 2: 125-153, 1990.
33. PRODY, C. A., DREYFUS, P., ZAMIR, R., ZAKUT, H. AND SOREQ, H.: De Novo amplification within a "silent" human cholinesterase gene in a family subjected to prolonged exposure to organophosphorous insecticides. Proc. Natl Acad. Sci. U.S.A. 86: 690-694, 1989.
34. RADIC, Z., PICKERING, N. A., VELLOM, D. C., CAMP, S. AND TAYLOR, P.: Three distinct domains in the cholinesterase molecule confer selectivity for acetyl-and butyrylcholinesterase inhibitors. Biochemistry 32: 12074-12084, 1993.
35. RAINER, M., MARK, T. AND HAUSHOFER, A.: Galanthamine hydrobromide in the treatment of senile dementia of Alzheimer's type. In Pharmacological Interventions on Central Cholinergic Mechanisms in Senile Dementia, ed. by H. Kewitz and U. Bickel, pp. 233-237, W Zuckschwerdt Verlag, München, 1989.
36. RUSH, D. K.: Scopolamine amnesia of passive avoidance: A deficit of information acquisition. Behav. Neural Biol. 50: 255-274, 1988.
37. RUSH, D. K. AND STREIT, K.: Memory modulation with peripherally acting cholinergic drugs. Psychopharmacology 106: 375-382, 1992.
38. SCHUH, F. T.: Molecular mechanism of action of galanthamine, a curare antagonist. Anaesthesist 25: 444-448, 1976.
39. SEGEL, I. H.: Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, pp. 107-111, 132-134, John Wiley & Sons, Inc., New York, NY, 1975.
40. SHUTSKE, G. M., PIERRAT, F. A., KAPPLES, K. J., CORNFELDT, M. L., SZEWCZAK, M. R., HUGER, F. P., BORES, G. M., HAROUTONIAN, V. AND DAVIS, K. L.: 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: Synthesis and evaluation as potential Alzheimer's disease therapeutics. J. Med. Chem. 32: 1805-1813, 1989.
41. SWEENEY, J. E., BACHMAN, E. S. AND COYLE, J. T.: Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacology 102: 191-200, 1990.
42. SWEENEY, J. E., PUTTFARCKEN, P. S. AND COYLE, J. T.: Galanthamine, an acetylcholinesterase inhibitor: A time course of the effects on performance and neurochemical parameters in mice. Pharmacol. Biochem. Behav. 34: 129-137, 1989.
43. TAYLOR, P.: The cholinesterases. J. Biol. Chem. 266: 4025-4028, 1991.
44. THOMSEN, T., BICKEL, U., FISCHER, J. P. AND KEWITZ, H.: Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1: 46-51, 1990.
45. THOMSEN, T. AND KEWITZ, H.: Comparison of acetyl- and butyrylcholinesterase inhibition as due to reversible enzyme inhibitors. Clin. Biochem. 22: 411, 1989.
46. THOMSEN, T. AND KEWITZ, H.: Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci. 46: 1553-1558, 1990.
47. THOMSEN, T , ZENDEH, B., FISCHER, J P. AND KEWITZ, H.: In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers. Biochem. Pharmacol. 41: 139-141, 1991.
48. WHITEHOUSE, P. J., PRICE, D. L., CLARK, A. W., COYLE, J. T. AND DELONG, M. R.: Alzheimer's disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol 10: 122, 1981.
49. WILLIAMS, J. W. AND MORRISON, J. F.: The kinetics of reversible tight-binding inhibition. In Methods in Enzymology, ed. by D. L Purich, vol. 63, part A, pp. 437-467, Academic Press Inc., New York, NY, 1979.